Skip to main content
TipRanks
Go Ultimate75% OFF

Scancell Holdings (SCNLF) AI Stock Analysis

19 Followers
SCNLF

Scancell Holdings

(Other OTC:SCNLF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
FDA-cleared Phase III pathwayFDA clearance validates the planned Phase III design, manufacturing package, endpoints, and statistical approach, materially reducing regulatory execution uncertainty. The surrogate endpoint could support an accelerated approval route, creating a clearer development and commercialization pathway if efficacy is confirmed.
Negative Factors
Negative equity and asset deteriorationNegative equity and a sharply reduced asset base indicate limited balance-sheet resilience relative to the company’s development obligations. With debt still about £17.1m, Scancell has less financial flexibility to absorb setbacks or fund strategic programs without additional external capital.

Scancell Holdings (SCNLF) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%SCNLF-22.96%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$96.74M
Dividend Yield
―
Average Volume (3M)
1,537
Price to Earnings (P/E)
-4.6
Beta (1Y)
0.50
Revenue Growth
-100.00%
EPS Growth
-35.56%
Country
US
Employees
60
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Scancell Holdings Business Overview & Revenue Model

Company Description

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The c...

Scancell Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SCNLF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:4BBGB:4BB52NeutralGBP 100.70M-4.53-316.73%―-56.10%-16.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:SARGB:SAR47NeutralGBP 23.75M-6.04-188.01%――28.78%
GB:POLBGB:POLB42NeutralGBP 48.10M-8.08-71.28%――31.58%
GB:OBIGB:OBI40UnderperformGBP 57.20M-2.52-9999.00%―26.99%4.36%
GB:ARECGB:AREC33UnderperformGBP 34.43M152.003.75%―――

* Healthcare Sector Average

Performance Comparison

0%50%100%150%SCNLFGB:SARGB:4BBGB:POLBGB:ARECGB:OBIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SCNLF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SCNLFScancell Holdings1.04-0.31-22.96%
GB:SARSareum Holdings14.501.7513.73%
GB:4BB4basebio UK Societas525.00-187.50-26.32%
GB:POLBPoolbeg Pharma Ltd.6.302.7075.00%
GB:ARECArecor Therapeutics PLC76.002.002.70%
GB:OBIOndine Biomedical, Inc.8.65-2.60-23.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.